The Organising Committee of the Forensic & Clinical Toxicology Association Conference 2024 is delighted to have three wonderful Keynote Speakers joining us in Hobart for the conference.
International Keynote Speaker
National Keynote Speakers
A/Prof Christophe Stove
Christophe Stove, PharmD, PhD is associate-professor at Ghent University, heading the Laboratory of Toxicology at the Faculty of Pharmaceutical Sciences. Besides teaching some 5 courses (amongst which toxicology, drug toxicity and bioanalysis), he directs the Lab’s service activities (forensic toxicology and reference laboratory activities) and steers the research. The latter covers applied cell biology, as well as bioanalysis. Topics include the evaluation of signaling at selected G protein-coupled receptors, the pharmacological characterization of new psychoactive substances, the development of bio-assays as an alternative and universal drug screening approach in forensic toxicology and doping, as well as vitamer analysis and microsampling applications and associated challenges in the context of therapeutic drug monitoring. The lab’s work has resulted in several national and international awards and prizes.
Dr. Stove has an extensive publication record (some 240 publications, of which over 100 during the past 3 years), with many publications in leading journals in the field, and he serves as a corresponding author on the vast majority of these. He has an H-index of 48, has been cited over 7000 times (Google Scholar), is editorial board member of several journals and has served in numerous PhD evaluation and (inter)national selection committees. He was the promotor of 20 defended PhDs and currently supervises 8 PhD students. He is currently Board/Council Member of 2 national (BLT, KBGGG) and 2 international (TIAFT and IATDMCT) associations.
A/Prof Rebecca McKetin
A/Prof Rebecca McKetin (BSc(Psychol)Hons. PhD) leads a program of research into stimulant use epidemiology and interventions at the National Drug and Alcohol Research Centre, UNSW.
Her current research involves trialling new pharmacotherapy options for methamphetamine dependence (www.tinatrial.info, www.nicetrial.info; www.limastudy.info) the development of novel responses to methamphetamine use in Aboriginal and Torres Strait Islander communities (www.nimac.org.au), the online delivery of psychological help for people who use stimulants (www.breakingtheice.org.au, www.wecandothis.com.au) and the translation of contingency management for stimulant use into Australian clinical practice.
Her work has been pivotal in quantifying the extent of methamphetamine use in Australia and related health outcomes. She is a Senior Editor for Addiction, a member of the UNSW Academic Board, a consultant to the United Nations, a former NSW/ACT Young Tall Poppy, and a member of the Australian Institute of Policy and Science.
Dr Paul Liknaitzky
Head, The Clinical Psychedelic Lab
Dept of Psychiatry, School of Clinical Sciences
Monash University
Paul Liknaitzky is Head of the Clinical Psychedelic Lab, and Senior Research Fellow within the Dept of Psychiatry at Monash University. He has played a central role in establishing the field of clinical psychedelic research in Australia, and is the Principal Investigator on a program of psychedelic trials. He leads the country’s largest and most experienced group of psychedelic researchers and clinicians, is involved in numerous psychedelic studies across the country, and collaborates with many international experts and organisations in the field.
Dr Liknaitzky has led several world-first studies, including the first trial to use psilocybin in the treatment of a primary anxiety condition, the first study testing the utility of psilocybin as a therapist training tool, and the first trial testing a psychedelic-augmented virtual-reality treatment. In Australia, he established the first psychedelic lab, coordinated the first applied psychedelic therapist training program, and obtained the first industry funding for psychedelic research. Together with clinical and industry colleagues, Dr Liknaitzky co-founded Australia’s first purpose-built psychedelic-assisted therapy clinic.
He is regularly invited to speak on psychedelic science for academia, medical peak bodies, industry, and government, and has been interviewed on the topic for television, documentaries, print media, radio, and podcasts. He co-convenes the Australasian Research Group on Psychedelic Science, and is a member of several Scientific Advisory Boards.
His work is focused on investigating novel applications for psychedelic therapies, translating evidence into best clinical practice, exploring under-examined risks, delivering next-generation therapist training, and improving access and affordability.
Twitter: @pliknaitzky
Web: monash.edu/psychedelics
LINKEDIN: https://www.linkedin.com/in/plik/
See the Film: https://www.sbs.com.au/ondemand/tv-program/psychedelics-stepping-into-the-unknown/2307419715780